The development of therapeutic agents that modulate the immune system (IS) to induce or potentiate its anti-tumour activity has revolutionized cancer treatment in recent years. Focusing on the IS of the host rather than the tumour has proven to be an effective strategy in a number of tumours. However, this approach is not new. In the late 19th century, William Coley noticed that some patients affected by sarcoma had tumour response when injected locally with bacteria-derived toxins in what seemed to be an immune-driven effect [1].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kCa57I
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Kenaf is a multipurpose crop, but a lack of genetic information hinders genetic and molecular research. In this study, we aimed t...
-
As demonstrated by the market reactions to downgrades of various sovereign credit ratings in 2011, the credit rating agencies occupy an impo...
-
Spindle cell/pleomorphic lipoma is an uncommonly encountered benign neoplasm that is usually found in the subcutaneous tissues. Rare cases r...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iI98XR via IFTTT
-
ORIGINAL ARTICLES Cyclooxygenase-2 and estrogen receptor-β as possible therapeutic targets in desmoid tumors p. 47 Rasha A Khairy DOI :10....
-
Umbrella reviews: what they are and why we need them Cystic echinococcosis in unaccompanied minor refugees from Afghanistan and the Middle E...
-
Abstract Despite the recent promising results of clinical trials using human pluripotent stem cell (hPSC)-based cell therapies for age-rel...
-
Lichtenstein intervention is currently the classic model of the regulated treatment of inguinal hernias by direct local approach. This “tens...
-
2016-09-29T05-30-58Z Source: Journal of Applied Pharmaceutical Science Sadhana Nittur Holla, Meena Kumari Kamal Kishore, Mohan Babu Amber...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου